Antares Pharma — Investor Presentation (January 2020)
27 slides from Antares Pharma's investor presentation, Jan 13, 2020
Slide 1: Antares Pharma Investor's Update January 2020
Antares Pharma Investor’s Update January 2020 EX 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those des
Slide 3: Who We Are
At Antares Pharma, we leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas. Who We Are Our novel drug delivery technology can provide multiple product opportunities and life-cycle management solutions Revenue streams
Slide 4: Antares Pharma Overview
Antares Pharma is an innovative leader in self-administered injection technology We are a commercial, revenue-generating Company which develops combination products focused on rescue therapies Five products utilizing Antares devices were commercialized in the past six years. The three most recent: X
Slide 5: Antares Pharma Snapshot
Dramatic growth in revenue vs. prior years $63.6 M million in product revenue Nine Month YTD 2019 – an 89% increase compared to the same period one year ago Nine Month YTD 2019 Proprietary Products Revenue: XYOSTED® and OTREXUP®: $25.2 M Nine Month YTD 2019 Partnered Products Revenue: Teva EpiPen Te
Slide 6: Antares Pharma Proprietary Commercial Products
Antares Pharma Proprietary Commercial Products January 2020
Slide 7: An innovative way to deliver testosterone replacement therapy
An innovative way to deliver testosterone (T) replacement therapy 98.5% of patients in a 52-week phase-3 study achieved testosterone levels in the normal, physiologic range at week 12 A narrow peak-to-trough ratio of 1.8 T Levels maintained for as long as the patient stays on therapy* Steady, predic
Slide 8: Ctrough Stable For Weeks
Ctrough Stable For 52 Weeks 6 12 18 26 38 52 Week 1, pre-dose Mean Ctrough (ng/dL) over 52 week “003” study Green lines represent the defined range of 300 – 1100 ng/dL ………….. Baseline QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL a
Slide 9: XYOSTED Monthly TRx Growth
More than 52,000 XYOSTED TRx to date written by over 4,000 different physicians More than 15,000 patients prescribed XYOSTED since launch Q3 2019 TRx increased 73% sequentially vs. Q219 As of October 1 ~72% of all commercial lives covered XYOSTED® Monthly TRx Growth 7,166 4,592 4,321 8,829 8,913
Slide 10: Broad XYOSTED Utilization Across all Specialties
Commercial Experience Broad XYOSTED® Utilization Across all Specialties* *Q419 IQVIA Data
Slide 11: Multiple Channels Directed at Key XYOSTED Targets
Trial Experience Multiple Channels Directed at Key XYOSTED® Targets Multi-channeling campaign targets physicians and patients through digital, social, enduring, and live platforms that drive awareness, prescription generation, and prescription fulfillment STEADYCare: Co-pay assistance for patients a
Slide 12: Antares Pharma Partnered Products
Antares Pharma Partnered Products January 2020
Slide 13: Teva's Generic EpiPen
Commercial Experience Teva’s Generic EpiPen Teva’s generic EpiPen® was approved by FDA as therapeutically equivalent to Mylan’s EpiPen® and is fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on in-market sales
Slide 14: Teva's Generic EpiPen Quarterly TRx Prescription Trends
Commercial Experience Teva’s Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions
Slide 15: Makena hydroxyprogesterone caproate injection
Commercial Experience Makena® hydroxyprogesterone caproate injection Makena® is to used to reduce the risk of pre-term birth in certain at-risk women Provides patients with efficient, discreet, and user-friendly administration AMAG/Antares collaboration began in 2014 Antares receives cost plus produ
Slide 16: Antares Pharma Development Pipeline
Antares Pharma Development Pipeline January 2020
Slide 17: Global Development Agreement with Idorsia for Selatogrel
Global Development Agreement with Idorsia for Selatogrel Antares entered into a global agreement with Idorsia Pharmaceuticals to develop a drug device product combining selatogrel, a New Chemical Entity - with the QuickShot Auto Injector Selatogrel is a fast acting and highly selective P2Y12 recepto
Slide 18: Myocardial infarction burden and selatogrel Phase II data
Around 7.6 million Americans have survived an MI (Myocardial Infarction) Each year, around 750,000 have a new or recurrent MI1 550,000 have a first MI - 200,000 have a recurrent MI Product justification Onset of action of all oral P2Y12 inhibitors may be delayed by up to 6 hours or more in the setti
Slide 19: Global Development Agreement with Idorsia for Selatogrel
Global Development Agreement with Idorsia for Selatogrel Idorsia will pay for the development of the combination product and take responsibility for obtaining global regulatory approvals Antares and Idorsia intend to enter into a separate license and commercial supply agreement under which Antares w
Slide 20: Generic Forteo (teriparatide) expected launch
Teva announced they expect generic teriparatide will be approved and launched in the second half of 2020* Teva has successfully completed a decentralized registration process in 17 countries in Europe and is waiting to launch globally According to Lilly’s 2018 form 10k, Forteo® full year revenues we
Slide 21: Diversified Combination Products Portfolio
Diversified Combination Products Portfolio DEVELOPMENT PRODUCT MOLECULE PRECLINICAL CLINICAL FILED APPROVED MARKETED ANTARES XYOSTED® TESTOSTERONE ANTARES OTREXUP® METHOTREXATE TEVA SUMATRIPTAN SUMATRIPTAN TEVA EPINEPHRINE EPINEPHRINE AMAG MAKENA® HYDROXYPROGRESTERONE TEVA TERIPARATIDE (EU) TERIPARA
Slide 22: Antares Pharma Q3 2019 Financial Results
Antares Pharma Q3 2019 Financial Results January 2020
Slide 23: Third Quarter and YTD 2019 Financial Results
Commercial Experience Third Quarter and YTD 2019 Financial Results Three Months Ended Sept 30 Increase Nine Months Ended Sept 30 Increase 2019 2018 (Decrease) 2019 2018 (Decrease) Total Revenue $ 34,306 $ 17,868 92% $ 86,025 $ 44,733 92% Cost of Revenue 13,062 7,289 79% 36,449 21,435 70% Gross Profi
Slide 24: Rapidly Growing and Diversified Revenue Mix
2016 Revenue Mix: $52.2M 2019 Year-to-Date Revenue Mix: $86.0M* Rapidly Growing and Diversified Revenue Mix 2017 Revenue Mix: $54.5M *Through September 30, 2019
Slide 25: 5-year Growth and 2019 Projection
+17% vs. 2017 +89% vs. 2018* 5-year Growth and 2019 Projection Projected CAGR of 35.3% * Percent increase based on high end of 2019 guidance +72% vs. 2014 +14% vs. 2015
Slide 26: Catalysts and Accomplishments
Catalysts Accomplishments Foundation Identify, develop, and commercialize important rescue and self-injection medicines Antares 2019: ‘A Transformational Year’ Potential 81% - 89% increase over 2018 reported revenue (2019 revenue guidance $115 - $120) Q3 2019 revenue of $34.3M, a 92% increase vs. Q3
Slide 27: Thank you / Questions
antares pharma Thank you Questions making medicines better fool
Antares Pharma — Investor Presentation (January 2020) on 6ix